From Alnylam Pharmaceuticals's results release of 2026年10月29日; its quarterly report has since been filed.

• Revenue

  Actual

  $1.46B

  +17% y/y ↑
  +13% q/q ↑

  Guided

  —

  No guide given

• EPS, GAAP

  Actual

  $15.72

  Guided

  —

  No guide given

• Operating income, GAAP

  Actual

  $345.8M

  -6.0% y/y ↓
  +49% q/q ↑

  Guided

  —

  No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.